Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

SAB Biotherapeutics

Request full access

A clinical-stage biopharmaceutical development company

Miami Beach, United StatesFounded 2014Biotech & Life Sciences

About SAB Biotherapeutics

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical firm that develops fully human polyclonal immunotherapeutic antibodies to address immunology disorders and infectious diseases. Founded in 2014 by Eddie J. Sullivan, Christine Hamilton, and Edward Hamilton, the company emerged from the 2014 merger of Sanford Applied Bioscience and BioDak. Dr. Sullivan, who has over 25 years of experience in biopharma leadership, currently serves as President, while Samuel J. Reich assumed the role of CEO in early 2024. The founders' journey is deeply connected to their background in large animal veterinary medicine and ranching, which provided the foundation for the company's core technology.

The company's core asset is its proprietary DiversitAb™ platform, which utilizes genetically engineered transchromosomic (Tc) cattle to produce targeted, high-potency, fully-human polyclonal antibodies without requiring human donors. This technology enables the rapid development of antibody therapeutics, with the potential to move a candidate from concept to clinic in under five months. SAB operates through a single segment focused on developing these therapies, with its headquarters and manufacturing facilities located in Sioux Falls, South Dakota.

SAB Biotherapeutics' business model is centered on advancing its pipeline of drug candidates through clinical trials to gain regulatory approval and eventual commercialization. Its revenue has historically been generated from government contracts and grants, including significant funding from the U.S. Department of Defense and BARDA for programs related to COVID-19 and influenza. For the fiscal year 2024, the company reported revenues of $1.32 million. A significant milestone was achieved in October 2021 when SAB became a publicly traded company on the Nasdaq (ticker: SABS) through a merger with Big Cypress Acquisition Corp., a special purpose acquisition company (SPAC). This transaction provided approximately $118 million in cash resources to fuel the development of its platform and pipeline.

The company's lead product candidate is SAB-142, a fully human anti-thymocyte globulin (hIgG) intended to delay the onset and progression of Type 1 Diabetes (T1D). SAB-142 has demonstrated a favorable safety profile in Phase 1 trials and is advancing toward a Phase 2b study. Other notable pipeline programs include SAB-176 for severe influenza, which has been granted Breakthrough Therapy and Fast Track designations by the FDA, and SAB-195 for Clostridioides difficile (C. diff) infection. The company serves a global market, targeting diseases with significant unmet medical needs, and collaborates with government agencies, academic institutions, and pharmaceutical companies to advance its research.

Source: Dealroom company data

At a glance

Status
Operational
Employees
90
Open positions
None listed
Dealroom signal
91.4/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, SPAC Target, SPAC IPO Announced, Woman Founder, DT and LS, science-based
Business model
Manufacturing

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITYOther financing Mar 2026 $85M — Undisclosed ↗
PRIVATE PLACEMENT VCOther financing Jul 2025 $175M — Blackstone · JDRF T1D Fund · Vivo Capital · ATW Partners ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

SAB Biotherapeutics website traffic

Latest recorded traffic for SAB Biotherapeutics is 11K monthly website visits, up 71.9% over the last three months. SAB Biotherapeutics's team grew 30.4% over the past year.

Latest monthly visits11K 3-month web change+71.9% 1-year team growth+30.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

SAB Biotherapeutics in the Miami Beach ecosystem

Live from Dealroom

The SAB Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

21 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • National Institutes of Health
  • HHS Administration for Strategic Preparedness and Response

Series A2 investors entered at this stage

  • Siouxfallsdevelopment
  • Merck & Co.

Series B and later2 investors entered at this stage

  • Big Cypress Acquisition
  • US Department of War

Other known investors15 additional known investors

  • Commodore Capital
  • JDRF T1D Fund
  • RA Capital Management
  • Sessa Capital
  • ATW Partners
  • Blackstone
  • BVF Partners
  • Forge Life Science Partners
  • Marshall Wace
  • RTW Investments
  • Sanofi
  • Spruce Street Capital
  • University of Massachusetts Amherst
  • Vivo Capital
  • Woodline Partners
Team profiled 15 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about SAB Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See SAB Biotherapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.